Stock Price Quote

CIPLA LTD.

NSE : CIPLABSE : 500087ISIN CODE : INE059A01026Industry : Pharmaceuticals & DrugsHouse : Cipla
BSE1500.95-1.3 (-0.09 %)
PREV CLOSE ( ) 1502.25
OPEN PRICE ( ) 1502.60
BID PRICE (QTY) 1499.70 (33)
OFFER PRICE (QTY) 1500.95 (15)
VOLUME 33398
TODAY'S LOW / HIGH ( )1492.00 1510.00
52 WK LOW / HIGH ( )1310.05 1702
NSE1499.10-3.1 (-0.21 %)
PREV CLOSE( ) 1502.20
OPEN PRICE ( ) 1509.70
BID PRICE (QTY) 1499.00 (2427)
OFFER PRICE (QTY) 1499.10 (202)
VOLUME 1586019
TODAY'S LOW / HIGH( ) 1492.00 1510.20
52 WK LOW / HIGH ( )1335 1702.05
1D 1M 3M 1Y 3Y 5Y

STOCK SUMMARY

Incorporation Year : 17-08 1935
Management Info
Y K Hamied - Chairman Umang Vohra - Managing Director
Registered Office

Address Cipla House, Peninsula Business Park,Ganpatrao Kadam Marg,Lower Parel,
Mumbai,
Maharashtra-400013

Phone 022-24826000

Email contactus@cipla.com

Website www.cipla.com

Registrars Details
K FIN Technologies Ltd.-(Karvy Fintech Pvt Ltd.)
Karvy Selenium Tower B, Plot 31-32,Gachibowli,Financial District,Nanakramguda,Hyderabad
Listing : BSE, NSE, Luxembourg

NEWS

13May Cipla reports 30% rise in Q4 consolida
Cipla has reported results for fourth quarter (Q4) and year ended March..
21Apr Cipla’s arm’s Goa facility classified
United States Food and Drug Administration (USFDA) has classified inspec..
11Apr Cipla informs about disclosure
Pursuant to the provisions of Regulation 30 read with Schedule III Part..
11Apr Cipla gets USFDA’s final approval for
Cipla has received final approval from the United States Food and Drug A..
11Apr Cipla jumps on getting USFDA’s final a
Cipla is currently trading at Rs. 1479.25, up by 62.95 points or 4.44% f..

Financials

in Millions
QTR Mar 25 ANNUAL 25
Net Profit1485451576.5
Gross Profit 17555.5 64688.2
Operating Profit 16120.867631.6
Net Sales 47978.9190448.5

ROLLING FORWARD P/E (EOD)

EVENT CALENDAR

peer group

Abbott India (BSE)
peergroup  30569.95 (0.65%)
M.Cap ( in Cr)66245.02
Divi's Lab (BSE)
peergroup  6282.00 (1.17%)
M.Cap ( in Cr)166130.24
Medplus Health Servi (BSE)
peergroup  881.20 (7.71%)
M.Cap ( in Cr)10162.01
Wockhardt (BSE)
peergroup  1330.70 (3.60%)
M.Cap ( in Cr)20967.95
Jubilant Pharmova (BSE)
peergroup  947.05 (4.54%)
M.Cap ( in Cr)14493.79

Shareholding Pattern

FI/BANKS/INSURANCE 5.99%
PROMOTERS 29.2%
MUTUAL FUNDS/UTI 20.51%
NON-INSTITUTION 16.38%
GOVERNMENT 0%
FII 0%

About Cipla Ltd.

Cipla Ltd. was incorporated in the year 1935. Its today's share price is 1500.95. Its current market capitalisation stands at Rs 120863.39 Cr. In the latest quarter, company has reported Gross Sales of Rs. 174829.8 Cr and Total Income of Rs.176450 Cr. The company's management includes Kamil Hamied, Maya Hari, Sharmila Paranjpe, Abhijit Joshi, Adil Zainulbhai, Balram Bhargava, Mandar Purushottam Vaidya, Rajendra Chopra, Robert Stewart, PR Ramesh, Umang Vohra, Samina Hamied, Y K Hamied.

It is listed on the BSE with a BSE Code of 500087 , NSE with an NSE Symbol of CIPLA and ISIN of INE059A01026. It's Registered office is at Cipla House, Peninsula Business Park,Ganpatrao Kadam Marg,Lower ParelMumbai-400013, Maharashtra. Their Registrars are K FIN Technologies Ltd.-(Karvy Fintech Pvt Ltd.) It's auditors are RGN Price & Co, RS Bharucha & Co, V Sankar Aiyar & Co, Walker Chandiok & Co LLP

© NIRMAL BANG. All rights reserved

Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.

Open an Account
FOR AFREE *DEMAT & BROKING ACCOUNT

Please fill in the details below

Close X

(Note - You will receive a call from our sales executive)

CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.